Treatment of Parkinson's Disease
Parkinson's disease is a progressive neurological disorder affecting movement, caused by the loss of dopamine-producing neurons. Symptoms include tremor, rigidity, slowness of movement, and balance problems. There is no cure, but treatments can manage symptoms.
Managing Parkinson's Disease effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Parkinson's Disease can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Accurate diagnosis essential: neuroimaging (MRI preferred), EEG, CSF analysis as indicated
- ✓Monotherapy preferred for epilepsy before combination; balance efficacy vs. teratogenicity
- ✓Early migraine prophylaxis if >4 headache days/month or significant disability
- ✓Levodopa remains gold standard for Parkinson's motor symptoms
- ✓Stroke: thrombolysis within 4.5h; thrombectomy up to 24h in selected patients; early secondary prevention
What to Do Now
- Learn your personal risk factors for Parkinson's Disease (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Parkinson's Disease
- Use our AI symptom checker to assess whether your symptoms fit an early Parkinson's Disease pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Parkinson's Disease-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Medications Used in Parkinson's Disease
Levodopa is used in the treatment of Parkinson's disease to improve motor function by restoring or mimicking dopaminergic neurotransmission.
Carbidopa is used in the treatment of Parkinson's disease to improve motor function by restoring or mimicking dopaminergic neurotransmission.
Pramipexole is used in the treatment of Parkinson's disease to improve motor function by restoring or mimicking dopaminergic neurotransmission.
Ropinirole is used in the treatment of Parkinson's disease to improve motor function by restoring or mimicking dopaminergic neurotransmission.
Rotigotine is used in the treatment of Parkinson's disease to improve motor function by restoring or mimicking dopaminergic neurotransmission.
Selegiline is used in the treatment of Parkinson's disease to improve motor function by restoring or mimicking dopaminergic neurotransmission.
Rasagiline is used in the treatment of Parkinson's disease to improve motor function by restoring or mimicking dopaminergic neurotransmission.
Amantadine is used in the treatment of Parkinson's disease to improve motor function by restoring or mimicking dopaminergic neurotransmission.
Non-Pharmacological Management
- •Lifestyle triggers: identify and avoid migraine triggers (irregular sleep, skipped meals, alcohol, bright light)
- •Sleep hygiene: critical for epilepsy control and migraine management
- •Physiotherapy and occupational therapy: for Parkinson's, post-stroke rehabilitation, multiple sclerosis
- •Speech and language therapy: post-stroke, Parkinson's, ALS
- •Cognitive rehabilitation for dementia and post-stroke cognitive impairment
- •Seizure first aid education for patients and carers
- •Mediterranean diet: associated with reduced dementia risk and improved post-stroke outcomes
Treatment Goals
Monitoring Parameters
- ◆Seizure diary: frequency, type, duration — key for epilepsy drug titration
- ◆Cognitive function: MMSE/MoCA annually in dementia and Parkinson's
- ◆Motor function scales: UPDRS for Parkinson's; EDSS for MS; mRS for stroke
- ◆Drug levels: essential for phenytoin, carbamazepine, valproate — and lithium in psychiatric comorbidity
- ◆MRI: new or progressive neurological symptoms; MS disease activity monitoring
- ◆LFTs, FBC: valproate (hepatotoxicity, thrombocytopenia); carbamazepine (agranulocytosis)
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Parkinson's Disease — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Parkinson's Disease combined with new relevant symptoms
- ⚠Sudden worsening of Parkinson's Disease symptoms despite established treatment
Escalation Criteria
- →Status epilepticus: IV benzodiazepine, then anti-epileptic loading dose; ICU if refractory
- →Parkinson's motor fluctuations despite optimised oral therapy → LCIG, DBS, or apomorphine infusion consideration
- →MS relapse: high-dose IV methylprednisolone; assess for disease-modifying therapy escalation
- →Acute severe migraine / thunderclap headache → exclude subarachnoid haemorrhage (CT + LP)
Special Populations
Clinical Insights
Compare With Similar Conditions
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →